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Significance of this study
What is already known about this subject?
 ► The relationship between physical activity (PA) and 
type 2 diabetes (T2D) has been widely researched.
 ► Minimal progress has been made in the implemen-
tation of research findings within everyday diabetes 
care practice.
What are the new findings?
 ► The current 1-year intervention was delivered in a 
real setting and using existing healthcare staff.
 ► This paper shows that the ‘MOVEdiabetes’ interven-
tion was effective in increasing the PA levels in inac-
tive adults with T2D.
 ► Secondary outcomes showed positive changes in 
blood pressure and triglycerides.
How might these results change the focus of 
research or clinical practice?
 ► Personalized PA consultations can be delivered with-
in routine diabetes primary care.
 ► The role of the existing staff in diabetes primary 
care, namely dietitians, could be extended to deliv-
er PA promotional methods, including PA consulta-
tions, use of pedometers and ‘WhatsApp’ monthly 
messages.
AbStrAct
Objective This study examined the impact of a 
multicomponent intervention to increase physical activity 
(PA) in adults with type 2 diabetes (T2D) in Oman.
Research design and methods This is a cluster 
randomized controlled trial in eight primary health 
centers. Participants were physically inactive, aged 
≥18 years, and with no contraindication to PA. Patients 
attending intervention health centers (n=4) received 
the ‘MOVEdiabetes’ intervention, which consisted of 
personalized, individual face-to-face consultations by 
dietitians. Pedometers and monthly telephone WhatsApp 
messages were also used. Patients attending comparison 
health centers received usual care. The primary outcome 
was change in PA [Metabolic Equivalent(MET).min/week] 
after 12 months assessed by the Global Physical Activity 
Questionnaire. The secondary outcomes were changes in 
daily step counts, sitting time, weight, body mass index, 
glycated hemoglobin, blood pressure and lipids.
Results Of the 232 participants (59.1% female, mean 
(SD) age 44.2 (8.1) years), 75% completed the study. 
At 12 months, the mean change in  MET. min/ week was 
+631.3 (95% CI 369.4 to 893.2) in the intervention group 
(IG) vs +183.2 (95% CI 83.3 to 283.0) in the comparison 
group, with a significant between-group difference of 
+447.4 (95% CI 150.7 to 744.1). The odds of meeting PA 
recommendations were 1.9 times higher in the IG (95% CI 
1.2 to 3.3). Significant between-group differences in favor 
of IG were detected for mean steps/day (+757, 95% CI 
18 to 1531) and sitting time hours/ per day (−1.5, 95% CI 
−2.4 to −0.7). Clinical measures of systolic and diastolic 
blood pressure and triglycerides also showed significant 
intervention effects.
Conclusions ‘MOVEdiabetes’ was effective in increasing 
PA, the likelihood of meeting PA recommendations, and 
providing cardioprotective benefits in adults with T2D 
attending primary care.
InTROduCTIOn
Similar to global trends, diabetes prevalence 
in Oman is increasing. Recent estimates 
in Omani adults are in the order of 12.6%, 
which is exceeding global rates.1 This increase 
is predominantly in type 2 diabetes (T2D), 
which is preventable through lifestyle modi-
fications.2 While diet and body weight are 
already part of routine diabetes management, 
physical activity (PA) advice and guidance is 
not routinely provided.
Evidence on the positive effects of PA on the 
management of T2D is strong, yet evidence 
on the effective ways for PA implementation 
as part of diabetes care is lagging behind.3 4 
Lifestyle modification including PA can result 
in improved glycemic control, lower blood 
sugar levels, reduced body fat, and a reduced 
risk of serious complications and premature 
mortality.5–7 To achieve clinical benefits, the 
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WHO recommends at least 150 min of moderate-in-
tensity PA or 75 min of vigorous-intensity PA per week, 
or a combination of the two.8 However, the majority of 
people with T2D are physically inactive compared with 
national norms in both Western (over 60% in USA)9 
and Arabic-speaking countries (over 80% in Oman and 
Lebanon).10 11
Current evidence on PA interventions in diabetes 
primary care comes mostly from Western countries, 
with mixed results.4 PA interventions have differed 
in their setting (clinical vs community), intervention 
methods (PA consultations, exercise sessions, or use of 
technology) and duration (short of 3–6 months vs long 
≥12 months).4 Incorporating behavior change tech-
niques (BCTs) in PA interventions has been shown to 
help individuals move from ‘inactive’ to ‘active’ stages 
of change for PA.12 While there are a large number of 
BCTs, these have been standardized by Abraham and 
Michie13 to assist the development of lifestyle interven-
tions, and more recent updates describe an extensive 
range of opportunities to assist the design of context-spe-
cific programs.13–15 However, further research is needed 
to establish how far the BCTs can lead to more efficient 
designs for improving the PA behaviors in the context of 
diabetes care.14 Avery et al12 (2012–2015) distinguished 
five context-appropriate BCTs for use during time-con-
strained consultations in diabetes care. These include 
‘prompt focus on past success’, ‘barrier identification’, 
‘use of follow-up prompts’, ‘providing information on 
where and when to perform the behaviour’ and ‘prompt 
review of behavioural goals of PA’.12 Further research is 
needed to investigate the BCTs that could be effective in 
promoting PA in Arabic-speaking countries.
Evidence on the effectiveness of personalized PA consul-
tations in clinical settings along with other supportive 
methods (eg, use of pedometers and telephones)15–17 
has been reported in many studies in the West, including 
guidelines on how to deliver them.18–21 To address the 
sociodemographic, cultural and clinical diversities, the 
impact of such approaches on PA promotion in local 
routine diabetes primary care setting in the Middle East 
is yet to be explored.
Consistent with the socioecological model of health 
behavior22 and the Behaviour Change Wheel model,14 
the work presented in this paper is underpinned by a 
series of formative studies undertaken in adults with T2D 
and diabetes primary care providers in Oman.23–25 The 
results showed that face-to-face PA consultations linked 
to BCTs, devices to support walking such as pedometers, 
and use of a telephone application (WhatsApp) could be 
promising components in an intervention design. Hence, 
these methods have been used in the ‘MOVEdiabetes’ 
intervention,26 the trial protocol for which is published 
elsewhere.26
The aim of this paper is to describe the effectiveness 
of the multicomponent ‘MOVEdiabetes’ intervention on 
change in PA levels  (primary outcome), and changes in 
objectively measured steps/day, sitting time (hours/ per 
day), weight, body mass index (BMI), glycated hemo-
globin (HbA1c), blood pressure and lipids (secondary 
outcomes).
MeTHOds
study design and randomization
The study was a 1-year (April 2016–June 2017) cluster 
randomized controlled trial of the ‘MOVEdiabetes’ inter-
vention versus usual care.26 Out of the 26 health centers 
in Muscat, 8 were randomly selected by an indepen-
dent statistician using random numbers table generated 
in SPSS V.22. Health centers were then randomized to 
deliver either the intervention in the intervention group 
(IG) health centers (n=4) or usual care in the compar-
ison group (CG) health centers (n=4).26
study population and recruitment
Eligible participants were adults aged ≥18 years with T2D 
who had been attending health centers for at least 6 
months for diabetes care and were screened by recruited 
project officers (POs) as being inactive using the Scot-
tish Physical Activity Screening Questionnaire,27 with no 
contraindication to increasing PA, and able to provide 
written informed consent.26
sample size
To demonstrate a 50% between-group difference in PA 
levels ( MET. min/ week) over 12 months, to be detected 
at a power of 80%, and a significance level of 5%, 128 
participants were required to complete the study (64 in 
each arm).26 This sample size (n) was calculated based 
on an estimation from formative work of the SD of mean 
PA levels of 145  MET. min/ week25 and mean sitting time 
(hours/day) of 0.2 with intraclass correlation coefficient 
of 0.1.28 Based on a dropout rate of 20%, 154 patients 
were required to participate (77 in each arm). Assuming a 
recruitment rate of 70%, it was estimated that 220 poten-
tial eligible patients were required to be approached.26
ethics
Ethical approval was obtained from the Omani Research 
and Ethical Review and Approve Committee in the 
Ministry of Health and reciprocally approved in the 
University of Dundee(online supplementary material 
1). In addition to providing informed consent, individ-
uals were given the right to withdraw consent for partic-
ipation in any aspect of this trial at any time without 
affecting their routine diabetes care. All participants 
were advised to report any serious adverse events occur-
ring throughout the trial as they would immediately be 
referred by the POs to their general practitioner.26
Training
Initially, three POs were recruited at each site (n=24) 
from the existing diabetes healthcare providers (doctors/
nurses/dietitians/health educators). POs received a 
5-day bespoke training program facilitated by a health 
psychologist and public health specialist from the UK 
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and local PA experts. The training included recruitment 
procedures, outcome measurements, and delivering the 
‘MOVEdiabetes’ intervention.26 More importantly, it was 
agreed by all the POs that the dietitians would conduct 
the PA consultations.24 This decision was based on discus-
sions guided by insights from healthcare professionals, 
reported in one of the formative studies, on extending 
the role of dietitians to deliver PA services within diabetes 
primary care.24
Measures/assessment instruments
A multicomponent questionnaire was developed, 
reviewed and approved by the research group and ethics 
committee. Except for the sociodemographic data at 
baseline, all primary and secondary outcome data were 
collected at baseline and at 3 and 12 months.26 The ques-
tionnaire included the following:
Sociodemographic data
Age, gender, marital status, education, and income were 
collected from the electronic health information system 
(HIS), and if data were missing they would be asked for 
it.
Metabolic and cardiovascular biomarkers
Weight, BMI (kg/m2), systolic and diastolic blood pres-
sure (mm Hg), HbA1c (%), and lipid profile (mmol/L) 
(total cholesterol, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL), triglycerides (TGs)) were 
collected from the HIS in the health center.
Levels of PA and sitting time
Self-perceived PA ( MET. min/ week) was estimated via 
face-to-face interviews using the Global Physical Activity 
Questionnaire (GPAQ).29 GPAQ is a 13-item PA ques-
tionnaire where levels of PA ( MET. min/ week) are 
estimated across work, travel and leisure domains.8 More-
over, objective assessment of PA (steps/day) and sitting 
time (hours/day) was carried out in a subset of selected 
subjects (40%). Initially all participants were offered 
accelerometers (activPAL micro, an ~20 g professional 
PA monitor)30 until the required numbers were reached. 
Application and removal of the accelerometers were 
performed in the health centers by the POs. The devices 
were programmed to continuously work for 7 days. 
They were wrapped in a plastic sleeve and then attached 
directly to the skin of the midline of the anterior aspect 
of the participant’s right thigh using an adhesive pad and 
tube bandages to keep the activity monitor in place.31 
Participants were asked to adhere to wearing the device 
for 24 hours for 7 days and record their sleeping/waking 
time and removal of the device in a daily log given to 
them. Participants were strongly advised not to remove 
the device unless for swimming activities or if they expe-
rienced an allergic reactions, but to contact the POs in 
their respected health center if such an instance arose.
Self-efficacy,32 social support,33 and a trial-specific 
self-assessed general health questionnaire26 were used 
at baseline and at 12 months. The results from these 
secondary outcomes will be presented in parallel papers.26
Blinding
Except for the sociodemographic data at baseline, all 
measures were collected by specialist diabetes nurses who 
were blinded to the study objectives and group alloca-
tion. Owing to the nature of this study, the POs could 
not be blinded to study objectives; however, they were not 
involved in data entry and/or analysis.
The ‘MOVediabetes’ intervention group
All patients are advised on diet and weight management 
as part of routine care, but there are no requirements 
to focus on PA. The ‘MOVEdiabetes’ intervention was 
undertaken as personalized face-to-face consultations 
(maximum 20 min) by trained dietitians on three occa-
sions (weeks 0, 4 and 8).26 The consultations aimed to 
encourage participants to achieve 150 min of moder-
ate-intensity or 75 min of vigorous-intensity PA (or a 
combination of the two) per week (≥600  MET. min/ week) 
at 12 months.26 The consultations were based on multiple 
BCTs reported in the ‘MOVEdiabetes’ study protocol.26 34 
The content of the consultations is described in figure 1.
It is estimated that a step count of no less than 6000–
7000 per day is required to achieve this goal.35 Hence, all 
participants were given pedometers (Yamax Digi-Walker 
SW-200, Yamasa Tokei Keiki, Tokyo, Japan) to record 
their daily step counts for self-motivation and moni-
toring. Feedback on step counts was given within the PA 
consultation visits and/or discussed over the WhatsApp 
telephone application.
Notably, all participants receiving the intervention acti-
vated their telephone WhatsApp application and received 
monthly messages from the POs in their respected health 
center.36 The messages were standardized to coincide 
with the international occasions/celebrations. These 
were hoped to motivate the participant to perform more 
PA (table 1). The messages were initially put in English 
and then translated to Arabic language to be sent to the 
participants. The content was reviewed and approved 
by the central and regional research ethical committees 
within the ‘MOVEdiabetes’ study protocol. POs initiated 
the WhatsApp groups, facilitated the conversations and 
monitored the group dynamics.
Comparison group
Participants allocated to the CG received no further 
study relevant contacts after 3 months measures until  the 
end of the study where they had their final measurments 
recorded at  12 months follow-up. 
statistical analysis
The quality of the entered data was cross-checked by staff 
trained in quality assurance using checklists specific to 
the study in a sample of 10% of questionnaires selected at 
random. Data were entered into Epi Info V.7,37 checked 
and cleaned prior to analysis. Entered data were trans-
ferred to IBM SPSS Statistics V.22.0 for Windows for 
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Figure 1 Content of the face-to-face personalized physical activity (PA) consultations.
Table 1 Content of WhatsApp monthly messages
Month Message Special occasion if any
May It is evident that regular physical activity of at least 150 min of moderate 
to vigorous intensity per week improves your body hemodynamics and 
blood glucose. Let’s start slowly and build up the amount of time and 
intensity of the activity.
World Hypertension Day
June Ramadhan is the month to fast from food and increase body movement, 
take this opportunity to increase your physical activity behavior.
Ramadhan
July Include physical activity in your happy social and religious events. Eid Al-Fitr
August Breast feeding is good for mothers and babies especially if it is 
complemented with healthy lifestyle including physical activity.
World Breast Feeding Week
September Pilgrim is the event that includes extensive physical activity. Increase your 
steps and keep on walking.
Eid Al-Adha
October Physical activity is good for prevention and management of cancer so try 
to reach to 10 000 steps a day.
Breast Cancer Awareness Day
November Celebrate the national day and have better diabetes control by increasing 
your daily walking steps.
Oman National Day and World Diabetes Day
December Aging is an unavoidable risk factor, prevent disability by increasing you 
physical activity.
International Day of Persons with Disability
January Start your new year with an aim to increase physical activity. New Year
February Being active physically is an important part of good health. 20–30 min 
of moderate to vigorous physical activity a day can help improve your 
health.
Healthy Lifestyle Awareness Day
March Women are more vulnerable to be physically inactive. Keep moving to 
stay healthy, strong and pretty.
International Women’s Day
April It is never too late to start being physically active. World Health Day
May Being physically active supports diabetes prevention and management. Ramadhan
Clinical Care/Education/Nutrition
analysis according to the GPAQ protocol.8 An intention-
to-treat analysis was performed according to the last value 
carried forward imputation for missing data at 3 and/or 
12 months, and a mean imputation procedure was done 
where baseline data were missing. Descriptive statistics 
were expressed as proportions, mean (SD), and median 
(IQR) at the study group level.
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Due to skewness of data obtained, a univariate analysis 
was done in two steps. Initially, for each outcome, differ-
ences at 3 and 12 months from baseline were calculated, 
and Mann-Whitney U tests used to estimate between-
group differences (intervention vs comparison) and 
the Wilcoxon signed-rank test to estimate within-group 
differences. Then, a time trend for treatment effect was 
estimated from a generalized linear model (GLM).
Furthermore, the primary outcome was dichotomized 
to meeting the WHO PA recommendations, if  MET. min/ 
week values were ≥600, and not meeting the recommen-
dations for <600  MET. min/ week. GLM was used to deter-
mine the between-group difference in meeting the PA 
recommendations at 3 and 12 months independently.
Moreover, within the IG, a multivariate analysis was 
carried out to identify potential correlates for changes 
in PA at 12 months across the studied sociodemographic 
characteristics.
Accelerometer data of valid days, defined as 24 hours 
of wear per day with an allowance of no more than 
4-hour removal time per day over the 7-day wear, with the 
monitor positioned in a dynamic axis orientation, were 
analyzed using a customized activPAL3 software.38 Prior 
to analysis, daily hours of sleep were estimated from the 
participants’ daily logs and eliminated from the outputs. 
The total number of steps per day and sitting time were 
then extracted from the accelerometer outputs, and 
between-group differences were explored.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for design or implementation of the 
study. No patients were asked to advise on interpretation 
or writing up of results. However, plans to disseminate 
the results of the research to study participants and rele-
vant patient community will be considered.
ResulTs
Recruitment, retention and attrition
Of the 441 participants who were screened for inactivity, 
232 (53%) consented to participate in the study. In total 
174 (75%) completed the study measurements at base-
line and at 3-month and 12-month follow-up (110 IG 
vs 105 CG, and 82 IG vs 92 CG, respectively). Figure 1 
presents the Consolidated Standards of Reporting Trials 
(CONSORT) flow chart that describes the progress of 
participants throughout the 12-month follow-up study.
Overall, out of 232 participants who provided consent, 
227 (97.8%) completed the baseline measurements, 215 
(92.7%) completed the 3-month follow-up measurements 
and 174 (75%) completed the final 12-month measure-
ments. The reasons for attrition (IG n=40, CG n=18) 
are presented in the CONSORT diagram (figure 2), 
and the most frequently reported reasons were feeling 
uncomfortable with the accelerometers (41%), joint pain 
(14%), travel outside of Oman (12%), or being lost to 
follow-up without a reason being given (17%).
Participants’ sociodemographic and physiological 
characteristics
At baseline, more than half of the participants in both 
the intervention and comparison groups were women 
(64.5% and 54.1%, respectively), and the mean age 
(SD) of the total population was 44.2 (8.1) with a range 
of 22–68 years. The majority of the population (79.3%) 
were married, and half (50.9%) had completed their 
secondary education. Income was reported by 87.5% of 
the total population, of which more than half reported 
a moderate income of ≤1000 Omani rials/month. Addi-
tionally, more than half of the total population were 
employed, with a higher percentage in the intervention 
than in the comparison group (65.6% vs 50%, respec-
tively). The two groups were similar in social status except 
for marital status (more married individuals in the CG vs 
IG) (p=0.03) and employment status (more employed 
individuals in the IG vs CG) (p=0.02) (table 2).
The mean (SD) duration of diabetes for the total popu-
lation was 5.8 (3.7) years, and 77.2% of them reported 
comorbidities, mainly hypertension (45.3%) or hyper-
lipidemia (35.6%) or both (15%), for which all were on 
antihypertensives or statins (lipid-reducing drugs) or 
both accordingly. Most (81%) of the sample (84.5% IG 
vs 77.3% CG) were on oral hypoglycemic drugs, of which 
13.8% also used insulin (9.8% IG vs 18.2% CG; p=0.07) 
(table 2).
At baseline, the mean (SD) BMI was >30 (8.3) kg/m2 
in both groups. The mean systolic blood pressure (SBP) 
levels were within the target levels of <140 mm Hg in 
both groups. The mean (SD) diastolic blood pressure 
(DBP) was significantly higher in the IG (83.2 (9.4) mm 
Hg) than in the CG (78.7 (14.4) mm Hg) (p=0.003). 
The mean (SD) HbA1c in both groups was >7.0% (8.1 
(1.7)% IG vs 7.8 (1.7)% CG), indicating poor diabetes 
control according to the Omani diabetes management 
guidelines.39 The average levels of total cholesterol and 
LDL, in both groups, were higher than the target limits. 
However, HDL and TG levels were all within target limits. 
There were no significant between-group differences in 
BMI, SBP, HbA1c, and lipid profile at baseline (table 3).
Change in primary outcome (PA levels)
Overall, about two-thirds (68.9%) of the calculated PA 
level ( MET. min/ week) was attributed to leisure activity, 
followed by 28.6% by travel and 2.5% by work. The domi-
nance of leisure activity as the main contributor to the 
overall PA levels was prominent in both groups at all 
measurement points.
At baseline there was no difference in median PA levels 
between the groups (p=0.08). However, at 3-month and 
12-month follow-up, the median (IQR) change in PA from 
baseline was significantly greater in the IG than in the CG 
at both time-points: +17% at 3 months (+140 (0–480) vs 0 
(0–330)  MET. min/ week, respectively; p=0.04) and +26% 
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Figure 2 Consolidated Standards of Reporting Trials flow chart describing progress of participants through the 12-month 
follow-up study.
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Table 2 Participants’ sociodemographic characteristics in the treatment group
Characteristics
Intervention group
n=122 (52.6%)
Comparison group
n=110 (47.4)
Total population
n=232 (%)
Gender 
  Male 56 (45.9) 39 (35.5) 95 (40.9)
  Female 66 (54.1) 71 (64.5) 137 (59.1)
Age (years) 
  Mean (SD) 43.5 (7.1) 45.1 (9.2) 44.2 (8.1)
  ≤44 65 (53.3) 48 (43.6) 113 (48.7)
  >44 57 (46.7) 62 (56.4) 119 (51.3)
Marital status 
  Currently unmarried 32 (26.2) 16 (14.5) 48 (20.7)
  Currently married 90 (73.8) 94 (85.5) 184 (79.3)
Education 
  ≤Secondary 62 (50.8) 52 (47.3) 114 (49.1)
  >Secondary 60 (49.2) 58 (52.7) 118 (50.9)
Income (Omani rials)* 
  ≤1000 per month 70 (57.4) 55 (50) 125 (53.9)
  >1000 per month 41 (33.6) 37 (33.6) 78 (33.6)
Employment 
  Currently unemployed 42 (34.4) 55 (50) 97 (41.8)
  Currently employed 80 (65.6) 55 (50) 135 (58.2)
Mean duration of diabetes (SD) 6.4 (4.5) 5.3 (2.6) 5.8 (3.7)
  ≤5 years 63 (51.6) 52 (47.3) 115 (49.6)
  >5 years 59 (48.4) 58 (52.7) 117 (50.4)
Comorbidities† 
  No comorbidities 27 (22.1) 26 (23.6) 53 (22.8)
  With comorbidities 95 (77.9) 84 (76.4) 179 (77.2)
Diabetes medication 
  Diet only 7 (5.7) 5 (4.5) 12 (5.2)
  Oral hypoglycemic drugs 103 (84.5) 85 (77.3) 188 (81.0)
  Oral hypoglycemic+insulin 12 (9.8) 20 (18.2) 32 (13.8)
*29 missing values due to reporting ’I don’t know’.
†Presence of hypertension, hyperlipidemia, thyroid, or any other condition coinciding with diabetes registered in the health information 
system.
Clinical Care/Education/Nutrition
at 12 months (+80 (0–663) vs 0 (−7.5–361)  MET. min/ 
week, respectively; p=0.01) (figure 3).
Additionally, figure 4 illustrates the steady increase in 
PA levels in both treatment groups, but in particular the 
significantly higher mean gain from baseline in the IG 
than in the CG at 12 months (+447.4 (95% CI 150.7 to 
744.1)  MET. min/ week, p=0.003) (table 2).
Within the IG, the gain in PA levels at 12 months was 
significantly associated with high education (+500  MET. 
min/ week, p=0.04, 95% CI 33.0 to 1144.4) and high 
income (+600  MET. min/ week, p=0.02, 95% CI 127.7 to 
1278.6).
Despite no significant differences at baseline, the odds 
of meeting the WHO PA recommendations were signifi-
cantly higher, by 1.8 (p=0.04, 95% CI 1.1 to 3.1) and 1.9 
(p=0.02, 95% CI 1.2 to 3.3) times, in the IG compared 
with the CG at 3 and 12 months, respectively (table 4).
secondary outcomes
Objectively measured step counts/day
Around half (48%) (n=59) of the participants in the IG 
vs 40% (n=44) in the CG used accelerometers at base-
line. Overall, 69 participants (67%) had completed accel-
erometer use at both baseline and 12 months (33 in the 
IG vs 36 from the CG). The average (SD) number of valid 
days (minimum of 4 valid days) at baseline and at 3 and 
12 months was 5.7 (1.0) (n=45), 5.3 (1.2) (n=38) and 5.3 
(1.3) (n=28) in the IG, and 5.9 (1.0) (n=39), 5.4 (0.93) 
(n=32) and 5.9 (1.1) (n=30) in the CG, respectively.
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Figure 3 Change in physical activity (PA) levels from baseline at 3 and 12 months by treatment group. MET, Metabolic 
Equivalent.
Clinical Care/Education/Nutrition
The average number of steps/day initially increased in 
the IG only at 3 months, thereafter increasing in both 
groups, such that the overall increase from baseline at 12 
months was significantly greater in the IG than in the CG 
(table 4). Overall at 12 months the average steps/day was 
+757 steps/day higher in the intervention compared with 
the comparison group (p=0.05, 95% CI −18 to −1531) 
(table 3).
Sitting time
Sitting time (hours/day) was found to change from 13.1 
(2.4) to 12.2 (1.9) at 3 months to 12.2 (2.2) at 12 months 
within the IG versus a change from 13.7 (1.0) at base-
line to 13.6 (1.2) at 3 months to 13.7 (1.4) at 12 months 
within the CG. Moreover, there was a significantly greater 
reduction in sitting time (hours/day) in the IG versus CG 
at both 3 and 12 months, by −1.3 (95% CI −2.2 to −0.6) 
and −1.5 (95% CI −2.4 to −0.7) hours per day, respectively 
(table 3).
Weight, BMI, HbA1c, BP, and lipid profile
Table 3 illustrates the lack of any between-group differ-
ences in changes in weight, BMI or HbA1c. However, 
there were significantly greater reductions in the IG 
compared with CG in SBP by −3.8 (95% CI −6.7 to −0.9) 
mm Hg (p=0.008) at 3 months and −1.8 (95% CI −2.6 to 
−0.7) mm Hg (p=0.04) at 12 months, and in DBP by −1.6 
(95% CI −2.6 to −0.7) mm Hg (p=0.001) at 12 months. 
Additionally, a significantly greater reduction in TG 
levels of −0.3 (95% CI −0.5 to −0.08) mmol/L (p=0.006) 
was observed in the IG versus CG.
Nonetheless, despite no between-group differences 
in change in weight, BMI and HbA1c, significant with-
in-group differences for median weight (p=≤0.001), BMI 
(p=≤0.001) and HbA1c (p=0.03) were found in the IG 
between baseline and 12 months.
Adverse events
Except for discomfort from accelerometer use, no 
adverse events reported by participants were considered 
to be related to participation in the trial in neither the IG 
nor the CG.
dIsCussIOn
The current study showed that the multicomponent 
‘MOVEdiabetes’ intervention, delivered by trained dieti-
tians, was effective in increasing PA levels in physically 
inactive adults with T2D within a local diabetes primary 
care setting at 12 months. The objective accelerom-
eter data also indicated a favorable increase in average 
number of steps/day in the IG. Similarly, objectively 
measured sitting time was reduced in the IG by −1.5 
hours/day more than in the CG.
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Figure 4 Mean (SE) change in mean physical activity levels (MET.min/week) in the treatment groups over 12 months. MET, 
Metabolic Equivalent..
Table 4 Odds of meeting PA recommendation at baseline and at 3 and 12 months between the treatment groups
n (%) 
Baseline (%) 3 months (%) 12 months (%)
OR
95% CI (p 
values) OR
95% CI (p 
values) OR
95% CI (p 
values)
Intervention
n=122 (52.6)
13 (10.7) 1.7 0.6 to 4.6 
(0.3)
46 (37.7) 1.8 1.1 to 3.1 
(0.04)
52 (42.6) 1.9 1.2 to 3.3 
(0.02)
Comparison
n=110 (47.4)
7 (6.4) Ref 28 (25.5) Ref 31 (28.2) Ref
PA, physical activity; Ref, reference.
Clinical Care/Education/Nutrition
Importantly, despite no significant changes in the 
metabolic outcomes (weight, BMI and HbA1c), the 
intervention showed favorable cardiovascular long-term 
outcomes,2 namely in reducing systolic and diastolic 
blood pressure and TGs at 12 months.
strengths and weaknesses of this study
This study makes a significant contribution to the current 
limited literature on translational research on effective 
PA interventions internationally and in particular in the 
Arab world.4
Strengths of the current study demonstrate the ability 
of existing health professionals, namely dietitians, to 
extend their roles and deliver the intervention in a rele-
vant clinical setting. Moreover, the use of physiological 
data from patients’ routine electronic medical records 
enabled the reporting of clinically relevant data.
This is the first trial to use accelerometers within the 
local clinical diabetes setting in Oman. Despite the 
complexity of data from the accelerometers pertaining 
to dropout and non-compliance to the 24-hour wear 
protocol, changes in average steps/day and sitting 
time were in favor of the IG at 12 months. This finding 
supports the positive effects of the ‘MOVEdiabetes’ inter-
vention on PA levels in the IG versus CG obtained from 
the self-reported questionnaire.
It should be noted that the trial sample size was calcu-
lated on the basis of detecting changes in the self-re-
ported PA questionnaire, not the accelerometers’ data. 
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Moreover, despite the fact that the aim of the trial was not 
to validate the tools, limitations of the self-reported PA 
data including the possibility of false reporting cannot be 
excluded.40 Hence, further exploration may be required 
to validate the subjective PA measurement tools (GPAQ), 
investigate reasons for non-adherence and identify ways 
to improve compliance to accelerometer use.
Moreover, consistent with the evidence on the domi-
nance of leisure time PA,41 the results from this study 
indicated the importance of leisure time activity in the 
overall increase in PA levels. However, a focus on the 
other PA domains (work and travel), where inactivity 
levels are more prominent, may be considered in further 
studies, especially given that more than half of the partic-
ipants in both groups were employed. This could include 
interventions to increase PA and reduce sitting time at 
workplaces via walk and talk meetings, marked worksite 
walking paths, standing desks and interrupted screen 
time programs.42
strengths and weakness in relation to other studies
The intervention used in this trial included support 
provided via WhatsApp messages. To our knowledge, 
this is the first study to integrate such technology-based 
approach as a long-term support tool within a PA inter-
vention study in Oman. It is possible that this approach 
could escalate trust between participants and POs in 
their respected health centers that facilitated sharing of 
information, and seeking support and feedback when 
needed.43 However, a study in Spain reported minor 
effects from WhatsApp-based interventions to promote 
PA training compared with face-to-face interventions.44 
These results could be affected by cultural differences 
or the short study duration (10 weeks) and/or small 
sample size (n=32) in the latter study. Therefore, further 
research is needed on the use of WhatsApp and/or any 
other texting applications in promoting PA in clinical 
settings (alone and as part of an intervention design).
Notably, similar to other studies, high education45 
and high income46 were associated with the long-term 
increase in PA levels within the IG. This finding may be 
linked to greater awareness of health issues and greater 
purchasing capacity for resources, such as46 pedometers, 
watches, treadmills or gym memberships, which could 
facilitate positive PA behavior change in higher socioeco-
nomic groups.47
It is notable that throughout the study period, sitting 
time was high (≥10 hours/day), exceeding the time 
reported in other studies in Oman.48 This is an important 
finding because sitting more than 8 hours/day increases 
the risk of all-cause mortality (even among individuals 
achieving the recommended 150 min/week of PA).49 It is 
possible that timing of data collection, population char-
acteristics and cultural norms may have been different 
across those studies that have investigated this relation-
ship. As such, addressing long sitting time patterns is 
required in further studies.30
The results from this study indicate a relatively small 
effect size; however, short-term and long-term odds of 
meeting the PA recommendation of ≥600  MET. min/ 
week were significantly higher in the intervention versus 
comparison group (table 4), indicating potential clinical 
benefits of the ‘MOVEdiabetes’ intervention on general 
health. Other benefits related to body composition were 
not explored in this study; however, the results showed 
positive effects of the ‘MOVEdiabetes’ intervention 
on lowering blood pressure and TG levels, indicating 
possible cardioprotective benefits.
The lack of a significant impact on the secondary 
outcomes, namely weight, BMI and HbA1c, is not unex-
pected given the intervention focused on PA alone 
(because usual care already provided advice on diet or 
weight management). More importantly, this result may 
be attributed to limited power to detect an intervention 
effect. Future adequately powered studies are required 
to better understand the impact of this intervention on 
secondary outcomes, including the biomedical, meta-
bolic and cardiovascular markers.
Implications of the study for clinicians and policy makers
Given the rising trends of diabetes and physical inactivity 
in Oman, this study provides a potential and pragmatic 
platform for recommendations for greater integration of 
PA in the management of diabetes. The multidisciplinary 
approach applied in this intervention provided potential 
solutions for perceived barriers by health professionals 
on promoting PA, namely lack of time and frequent staff 
turnover.24 Although dietitians were responsible for deliv-
ering the PA consultations, diabetes doctors and nurses 
were all involved to reinforce the same PA messages 
to the participants. Moreover, with respect to the PA 
consultation guidelines reported in the literature,19 50 51 
the guidelines on the personalized ‘MOVEdiabetes’ PA 
consultations within the current study could be further 
developed for consideration in future similar interven-
tions in the Arab world. Equally important, similar to an 
online training program for healthcare professionals on 
PA,52–54 the PA training linked to this study for the health-
care professionals could be adapted at regional and 
central health administrative levels to be used in future 
PA training activities.
unanswered questions and future research
A process analysis to assess the feasibility, appropriate-
ness and suitability of roll-out of this intervention is yet 
to be undertaken. Further studies are required to ensure 
that the increase in PA levels is sustainable. Moreover, 
although this trial was integrated within routine care, 
future cost analysis may be required to highlight any 
additional cost–benefit.
COnClusIOn
The ‘MOVEdiabetes’ intervention (face-to-face PA 
consultation delivered by a trained dietitian, with use of 
pedometers and WhatsApp telephone application for 
 o
n
 19 Novem
ber 2018 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2018-000605 on 31 October 2018. Downloaded from 
13BMJ Open Diab Res Care 2018;6:e000605. doi:10.1136/bmjdrc-2018-000605
Clinical Care/Education/Nutrition
self-monitoring and support) was effective in increasing 
short-term and long-term PA, reducing sitting time and 
increasing the likelihood of meeting the WHO PA recom-
mendations in adults with T2D attending their routine 
diabetes primary care clinics over 12 months. Addition-
ally, despite no significant impact on weight, BMI and 
HbA1c, the intervention showed potentially protective 
cardiovascular effectiveness, namely in reducing blood 
pressure and TG levels.
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